London, United Kingdom (CU)_ CorePath has teamed up with Cizzle Biotechnology, a diagnostics company based in the United Kingdom, to develop and market an exclusive early-stage lung cancer test across the United States. Lung cancer is the biggest cause of cancer-related mortality in the United States, accounting for over 25 percent of all cancer fatalities. Each year, lung cancer kills more individuals than the total count of colon, breast, and prostate cancers.
According to the American Cancer Society’s projections for lung cancer in the United States in 2022, the country records around 236,740 new cases of lung cancer every year, with 117,910 men and 118,880 women. Moreover, lung cancer causes around 130,180 fatalities each year, with 68,820 men and 61,360 women dying of the disease.
At present, there are no easy, specialized blood tests for early lung cancer diagnosis, despite the fact that focused therapies can enhance timely access to cancer care and save lives. However, it was reported that nearly eight million Americans are at high risk for lung cancer and should undergo yearly screening with low-dose CT scans. If only half of these people were examined, more than 12,000 lung cancer deaths could be avoided.
Dr. Aamir Ehsan, CEO and Medical Director of CorePath, expressed optimism over the partnership. He said, “As a board-certified hematopathologist and molecular geneticist, diagnosing cancer is hurting especially when cancer has already metastasized in patients. While efforts are underway to find actional genetic mutations to target treatment and improve survival, early detection and intervention are key to patients’ long-term survival and cure. The agreement with Cizzle Biotechnology represents a significant opportunity to provide early and cost-effective lung cancer detection via a simple and quick blood test which will result in significant cost savings downstream, avoiding expensive treatment, hospital admissions and ultimately saving lives.”
Allan Syms, Executive Chairman of Cizzle Biotechnology, expressed delight over the collaboration. He said, “Lung cancer is the leading cause of cancer deaths in the USA and a major health problem globally. This is because for many, detection of lung cancer only happens when it has become symptomatic and therefore more advanced, meaning 5-year survival rates are poor. The Company’s CIZ1B biomarker to detect early-stage lung cancer could represent a major breakthrough and we now have the opportunity to bring the benefits of this test to such an important market. We are delighted to be partnering with CorePath Laboratories who bring the expert knowledge and market reach to help develop our biomarker into a certified test that can be made available to patients and healthcare providers throughout the USA.”
